These findings suggest that OAS3 is an oncogene that is associated with tumour progression, can help to predict survival in patients with various tumours and is a potential biomarker for tumour prognosis, especially for the prognosis of PAAD, LUAD, KIRP, and UVM. This evidence concerns the gene OAS3 and pancreatic adenocarcinoma.